Newsroom

ESPOO, Finlândia & BANGALORE, Índia--(BUSINESS WIRE)--A QuantrolOx anunciou hoje um marco significativo em tecnologia quântica com o lançamento da VIDYAQAR, a primeira plataforma quântica de arquitetura verdadeiramente aberta do mundo, desenvolvida especificamente para educação, pesquisa, testes e benchmarking. O sistema foi apresentado hoje na Índia e estará disponível mundialmente no primeiro semestre de 2026. O nome VIDYAQAR deriva do sânscrito Vidyākar, que significa “promover sabedoria, co...

芬兰埃斯波与印度班加罗尔--(BUSINESS WIRE)--(美国商业资讯)-- QuantrolOx 今日宣布达成量子技术的重要里程碑，正式推出 VIDYAQAR——全球首个真正开放架构量子平台，专为教育、研究、测试与基准评测而设计。该系统今日于印度首次亮相，预计将于 2026 年上半年在全球上市。 VIDYAQAR 名称源自梵文 Vidyākar，意为“启迪智慧、赋予知识或科学”——这完美体现了该平台的使命：扩大先进量子硬件的普及性，并加速创新进程。 一个完整、开放且可扩展的量子平台 VIDYAQAR 是一个互联、完全开放架构的超导量子系统，整合了以下要素： 低温技术 控制电子设备 量子处理单元 (QPU) 集成式 Quantum EDGE 软件堆栈 VIDYAQAR 专为首次进入量子领域的组织设计，使团队能够在启用当天即可开始进行实验、无限制地自定义系统的每一层，并随时间扩展其基础设施。 这就是真正的开放架构：透明、灵活且模块化。 VIDYAQAR 的重要性 一个蓬勃发展的量子生态系统需要共享、开放的测试平台，让硬件、软件与控制方法能够进行原型设计、验证和基准评测。VIDYAQ...

PALO ALTO, Calif. e ROMA--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), azienda leader nel campo della diagnostica oncologica di precisione, oggi ha annunciato il lancio di FPG 360, un servizio di test di biopsia liquida offerto in ospedale presso la Fondazione Policlinico Universitario Agostino Gemelli IRCCS (Policlinico Gemelli) a Roma. Questa collaborazione è l'ultima in una serie di partnership tra aziende pubbliche e private formate da Guardant Health con ospedali universitari e di...

PALO ALTO, Californie et ROME--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq : GH), une société leader dans le domaine de l’oncologie de précision, a annoncé aujourd’hui le lancement réussi de FPG 360, un service interne de test de biopsie liquide à la Fondazione Policlinico Universitario Agostino Gemelli IRCCS (Policlinico Gemelli) à Rome, en Italie. Ce partenariat s’inscrit dans le cadre d’une série d’accords public-privé conclus par Guardant Health avec des hôpitaux universitaires et de rec...

BOSTON--(BUSINESS WIRE)--Phare Bio, a biotech social venture harnessing artificial intelligence to accelerate antibiotic discovery and development, and Basilea Pharmaceutica, a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today a strategic partnership to jointly develop a novel broad-spectrum antibiotic to address critical unmet needs for patients battling life-threatening infections caused by high-p...

PALO ALTO, Calif. & ROME--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), een toonaangevend bedrijf in precisie-oncologie, heeft vandaag de succesvolle lancering aangekondigd van FPG 360, een eigen testdienst voor vloeibare biopsieën bij de Fondazione Policlinico Universitario Agostino Gemelli IRCCS (Policlinico Gemelli) in Rome, Italië. Deze samenwerking is de nieuwste in een reeks publiek-private samenwerkingen die Guardant Health is aangegaan met vooraanstaande Europese academische en o...

SINGAPORE--(BUSINESS WIRE)--With reference to the press release dated 2 December 2025 by BW LPG Limited (“BW LPG” or the “Company”, OSE ticker code: “BWLPG.OL”, NYSE ticker code “BWLP”) on key information relating to the cash dividend for Q3 2025, the shares of the Company will be traded ex-dividend on the Oslo Stock Exchange from today and from 12 December 2025 on the New York Stock Exchange. About BW LPG BW LPG is the world’s leading owner and operator of LPG vessels, owning and operating a f...

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today released its 2026 financial calendar: March 26, 2026: Publication of 2025 financial statements May 13, 2026: Publication of revenue and cash position for 1Q2026 May 21, 2026: Annual General Shareholders Meeting September 17, 2026: Publication of half year financial statements November 5, 2026: Publication of revenue and cash position for 3Q2026 All financia...

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the first patient enrollment for its phase II study investigating the efficacy and safety of nemolizumab in treating patients living with Chronic Pruritus of Unknown Origin (CPUO). The first patient of the trial – which is taking place in the United States – was enrolled at Dr. Vlada Groysman’s site in Birmingham, Alabama. CPUO is an underdiagnosed condition defined as itch lastin...

MARSEILLE--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris : IPH ; Nasdaq : IPHA) (« Innate » ou la « Société ») publie aujourd’hui son calendrier financier pour l’année 2026 : 26 mars 2026 : Publication des résultats annuels 2025. 13 mai 2026 : Publication du chiffre d’affaires et de la position de trésorerie au premier trimestre 2026. 21 mai 2026 : Assemblée générale annuelle. 17 septembre 2026 : Publication des résultats semestriels 2026. 5 novembre 2026 : Publication du c...